| Clinical Diabetes/Therapeutics
Clinical Diabetes/Therapeutics

Efficacy and Safety of Dulaglutide 3 mg and 4.5 mg vs. Dulaglutide 1.5 mg: 52-Week Results from AWARD-11

book_2 Source: ADA 2020 - Oral session
calendar_today Published on Medfyle: June 2020
import_contacts 7 min
headphones 4 min

In this medfyle

Expert Commentary by Paolo Fiorina, MD, PhD and Ida Pastore, MD

This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.

Read more arrow_downward Hide arrow_upward

This is a highlights summary of an oral session given at the ADA 2020 - 80th Scientific Sessions and presented by:

Juan P. Frias, MD
National Research Institute, Los Angeles, CA, USA

The content is produced by Infomedica, the official reporting partner of ADA 2020 Virtual Meeting. The summary text was drafted by Patrick Moore, PhD, and reviewed by Marco Gallo, MD, an independent external expert, and approved by Dana M. Dabelea, MD, PhD, the scientific editor of the program.

The presenting authors of the original session had no part in the creation of this conference highlights summary.

In addition, an expert commentary on the topic has been provided by:

Paolo Fiorina, MD, PhD and Ida Pastore, MD

About the Experts
Read more arrow_downward Hide arrow_upward

Paolo Fiorina, MD, PhD is an endocrinologist. He is Director, International Center for T1D, Romeo ed Enrica Invernizzi Pediatric, University of Milan, Italy; Professor of Endocrinology, L. Sacco Hospital, University of Milan; Chief of Division of Endocrinology, ASST Sacco-Fatebenefratelli, Milan, Italy and Lecturer on Pediatrics, Boston Children’s Hospital, Harvard Medical School. He is actively involved in the Grant Committee of JDRF, Medical Science Review Committee (MSRC) for Islet Biology and Transplantation, Transplant Meeting Committee at the San Raffaele Hospital (Milan), American Heart Association (AHA), and American Society of Transplantation (AST).

He published over 140 peer-reviewed manuscripts (5700+ citations, h-index 44). He is focused in devising new immune-based preventive and therapeutic strategies for autoimmune diseases. His publication track record includes seminal contribution to the field of immunotherapy for the treatment of type 1 diabetes and of transplantation and stem cells to prevent and treat autoimmune diabetes and allograft rejection.

Ida Pastore, MD is an endocrinologist. She is a clinician and researcher at Division of Endocrinology, ASST Sacco-Fatebenefratelli, Milan, Italy, from 2020. Her research interests include type 2 diabetes and cardiovascular disease, gestational diabetes and type 1 diabetes. Her work is published in peer-reviewed journals in the field of diabetology.